T Acute Lymphoblastic Leukemia Clinical Trials

21 clinical trials for T Acute Lymphoblastic Leukemia across international registries, including 5 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma — RECRUITING · PHASE2
• Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia — RECRUITING · PHASE2
• Use of a New Medicine "Daratumumab" to Treat Left-over Cancer in a Blood Cancer Called "T Acute Lymphoblastic Leukemia" — RECRUITING · PHASE2
• Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations — RECRUITING · PHASE2
• Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-ALL — RECRUITING · PHASE1
• Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) — NOT_YET_RECRUITING · PHASE2
• Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma — ACTIVE_NOT_RECRUITING · PHASE3
• Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma — COMPLETED · PHASE3
• Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment — NOT_YET_RECRUITING · PHASE2
• Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting — ACTIVE_NOT_RECRUITING · PHASE2
• Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia — ACTIVE_NOT_RECRUITING · PHASE3
• Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALL — NOT_YET_RECRUITING · PHASE1
• Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia — COMPLETED · PHASE2
• Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) — WITHDRAWN · PHASE2
• Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL — OTHER · NA
• BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma — TERMINATED · PHASE2
• EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia — TERMINATED · PHASE1
• Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies — OTHER · PHASE1
• RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL — OTHER · NA
• Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia — TERMINATED · PHASE2
• Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma — WITHDRAWN · PHASE2

Refine this search